AnnaKukharenok

Associate

Irvine + 1.949.553.7565

Connect:

Share

Anna Kukharenok advises public and private companies on corporate law matters. She has represented clients in domestic and cross-border mergers, acquisitions, financings, corporate restructurings, and other strategic transactions.

Anna has represented clients in a range of industries, including real estate, technology, and life sciences. Her recent representations include Astellas Pharma in its $5.9 billion acquisition of Iveric Bio and Organon & Co. in its strategic investment in Claria Medical. In addition, she has experience advising companies on corporate governance matters.

Anna also maintains an active pro bono practice, assisting nonprofits in their corporate governance matters and representing individuals seeking asylum in the United States.

Anna is author of "From Bus Bans on Religious Advertisements to Beyond: Why Religion Is More Appropriately Classified as a Viewpoint Rather Than a Subject Matter, 59 San Diego L. Rev. 531 (2022).

Experience

  • Silicon Mobility sold to IntelJones Day advised Silicon Mobility SAS in the acquisition of the company by Intel Corporation.
  • Shiseido Americas acquires Dr. Dennis Gross Skincare for $450 millionJones Day is advising Shiseido Americas Corporation, a subsidiary of Shiseido Co., Ltd., regarding its definitive agreement to acquire DDG Skincare Holdings LLC, the owner of Dr. Dennis Gross Skincare, for $450 million in cash.
  • TenCate Grass to sell majority interest in Company to Leonard Green & Partners, LPJones Day is advising the management team of TenCate Grass Holding B.V. in connection with Leonard Green & Partners, LP's acquisition of a majority stake in TenCate Grass from Crestview Partners and select other shareholders.
  • VSE acquires assets and license from HoneywellJones Day advised VSE Corporation in the $105 million asset purchase and perpetual license agreement to manufacture and support certain of Honeywell International’s fuel control systems on four key engine platforms.
  • Venezuelan victim of political persecution wins asylumJones Day obtained a grant of asylum on behalf of Client S, a Venezuelan woman persecuted for her political opposition to the dictatorial regime of Venezuelan President Nicolás Maduro.
  • Five9 acquires Aceyus for $82 millionJones Day represented Five9, Inc. in its acquisition of 100% of the equity of Aceyus, Inc. for $82 million in cash.
  • Sumitomo acquires assets and rights related to lefamulin from NabrivaJones Day advised Sumitomo Pharma Co., Ltd. in the acquisition of assets from Nabriva Therapeutics plc and various wholly-owned subsidiaries. This acquisition includes assets from the U.S., Ireland, and Austria in support of the development, manufacture, marketing and commercialization of lefamulin in the People’s Republic of China, Hong Kong, Macau and Taiwan.
  • Astellas acquires Iveric bioJones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
  • Meridian Bioscience agrees to be acquired by SD Biosensor and SJL Partners in $1.53 billion all-cash transactionJones Day advised Meridian Bioscience, Inc. in its $1.53 billion all-cash acquisition by SD Biosensor and SJL Partners.
  • Organon makes strategic investment in Claria MedicalJones Day advised Organon in the strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.
    • View All

    February 2024 White Paper

    2023 Securities Litigation Year in Review

    February 2023 White Paper

    2022 Securities Litigation Year in Review

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.